U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Thiazolidinediones

; .

Author Information and Affiliations

Last Update: February 20, 2023.

Continuing Education Activity

Thiazolidinediones are medications used to manage and treat type 2 diabetes mellitus. These medications may be acting as a nuclear transcription regulator and an insulin sensitizer. This activity illustrates the indications, mechanism of action, and contraindications for thiazolidinediones as valuable agents for managing type 2 diabetes.

Objectives:

  • Identify the mechanism of action of thiazolidinediones.
  • Describe the potential adverse effects of thiazolidinediones.
  • Outline appropriate monitoring for the toxicity of thiazolidinediones.
  • Review the importance of collaboration and coordination among the interprofessional team and how it can enhance patient care with thiazolidinedione therapy to improve patient outcomes for patients who have diabetes.
Access free multiple choice questions on this topic.

Indications

The use of thiazolidinediones, also called "glitazones," in managing type 2 diabetes can help with glycemic control and insulin resistance. There are two thiazolidinediones, rosiglitazone, and pioglitazone, currently approved by the FDA as monotherapy or combined with metformin or sulfonylureas to manage type 2 diabetes mellitus. These medications should be in conjunction with lifestyle modifications such as diet, exercise, and weight reduction. Thiazolidinediones may also be used to treat polycystic ovarian syndrome, as these may lead to improved endothelial function, improved ovulation, and reduction of insulin resistance.[1] Pioglitazone specifically reduces hepatic fat and may improve liver fibrosis in patients with nonalcoholic steatohepatitis (NASH); however, additional variables and risks require assessment in NASH patients.[2][3] The most significant advantage of TZDs is that they do not cause hypoglycemia as monotherapy and are not contraindicated in patients with renal disease. 

Mechanism of Action

Thiazolidinediones (TZDs) are insulin sensitizers that act on intracellular metabolic pathways to enhance insulin action and increase insulin sensitivity in critical tissues.[4] TZDs also increase adiponectin levels, decrease hepatic gluconeogenesis, and increase insulin-dependent glucose uptake in muscle and fat. Adiponectin, a cytokine secreted by fat tissue, increases insulin sensitivity, and fatty acid oxidation increases with TZD therapy.[1][5][6][7] 

TZDs function by regulating gene expression through binding to peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a nuclear transcription regulator.[6] Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated transcription factors of nuclear hormone receptors that regulate energy homeostasis. The genes activated by the PPAR-gamma subtype are present in muscle, fat, and liver, regulating glucose metabolism, fatty acid storage, and adipocyte differentiation.[8] The binding of TZD will induce a conformational change to alter gene expression of numerous pathways involved in metabolism regulation, including lipoprotein lipase, glucokinase, fatty acyl-CoA synthase, and others.[9]  PPAR-gamma agonists improve insulin resistance by increasing adiponectin, GLUT4 expression, and opposing the effect of TNF-alpha in adipocytes. Increased GLUT 4 expression will increase glucose uptake in adipocytes and skeletal muscle cells in response to insulin.[8]

In addition to their function in glycemic control and improvement of insulin resistance, TZDs potentially have anti-inflammatory and anti-cancer properties. There is evidence that TZDs may slow the progression of medial intimal thickening and decrease coronary intimal hyperplasia. Research has shown additional beneficial effects on endothelial function, atherogenesis, fibrinolysis, and ovarian steroidogenesis. Some studies demonstrated that activation of PPAR-gamma receptors could induce cancer cell apoptosis. However, these mechanisms are still under investigation due to conflicting studies and possible confounders.[1] 

Administration

Thiazolidinediones (TZDs) are taken orally once daily, with or without food. Before initiating treatment and periodically during therapy, LFTs and HbA1C levels require monitoring. Maximal glucose-lowering effects of TZDs are not seen for six weeks to 6 months due to a delayed onset of action via modification of gene expression. For type 2 diabetes management, TZDs should be used in combination with lifestyle modifications and can be used in conjunction with biguanides, sulfonylureas, and insulin injectables.[4][10] 

Dosing for treatment of T2DM:

  • Pioglitazone: Initial 15 to 30 mg PO with a meal once a day; may increase the dose by 15 mg with careful monitoring to 45 mg once a day. The maximum dose is 45 mg.
  • Rosiglitazone: Initial 4 mg PO once a day. If inadequate response after 8 to 12 weeks, may increase the dose to 8 mg PO once a day or 4 mg twice a day.

Adverse Effects

There are several undesirable side effects to thiazolidinediones, particularly with long-term use. The risks versus benefits require discussion with patients, and alternative first-line agents attempted before using TZDs. 

Edema and Congestive Heart Failure 

TZDs have been shown to cause dose-related fluid retention in up to 20% of patients. Methods of fluid retention include PPAR-gamma receptors in the distal nephron and insulin-activated epithelial sodium channels in the collecting tubules. PPAR-gamma activation stimulates sodium reabsorption, acting at the same site as aldosterone. Patients with preexisting edema or concomitant insulin therapy are at higher risk of edema and should start on the lowest available dose.[1][4][11] In most patients, fluid retention will respond to diuretics such as thiazides or spironolactone if the edema is mild or loop diuretics for severe cases. Furthermore, lower doses of 15 and 30 mg a day decreases the risk of edema and weight gain.

There are reports of an increase in intravascular volume to the point of congestive heart failure. Thus TZDs should be used with caution in patients with diastolic dysfunction or a history of CHF. The risk of heart failure and death is higher in rosiglitazone than pioglitazone.[12]

Weight Gain

Adipocytes have the highest concentration of PPAR-gamma receptors in the body. The mechanism behind the weight gain is due to a combination of factors. TZDs upregulate PPAR-gamma receptors in the central nervous system, leading to increased feeding. TZD agents expand adipose tissue mass via the maturation of preadipocytes into mature adipocytes and increase fat storage by increasing free fatty acid movement into cells. Additionally, fluid retention can increase weight.[4][13] Fat gain occurs primarily in the subcutaneous tissues, sparing the visceral area. As with edema and CHF, weight gain becomes exacerbated by concomitant insulin use, but the risk decreases when using metformin and lower doses of TZDs.

Fractures

Several studies have demonstrated an increased fracture risk and decreased bone density in patients taking TZDs compared to those taking insulin or other oral agents such as sulfonylureas. Proposed mechanisms for this include PPAR-gamma activation and insulin-like growth factor down-regulation, which diverts the differentiation of osteoblasts into adipocytes and leads to bone loss.[1][14] These fractures appear to be more likely in the distal extremities (forearm, wrist, ankle, foot, tibia) than the axial skeleton (hip, pelvis, femur). The fracture risk is further increased by additional risk factors, such as postmenopausal females or patients concurrently taking glucocorticoids or proton pump inhibitors (PPIs).[15][16][17]

Bladder Cancer

Pioglitazone has, in some studies, shown correlations with an increased risk of bladder cancer. This effect varies in a duration-dependent and dose-dependent fashion. Also, most recent analyses do not support an increased risk. In contrast, rosiglitazone was not associated with an increased risk of bladder cancer in any analysis, suggesting the risk is drug-specific and not a class effect.[18]

Hepatotoxicity

Troglitazone, the original PPAR-gamma activator, was removed from the market primarily due to hepatotoxicity. However, the other agents, rosiglitazone and pioglitazone, have rarely been linked to acute liver injury.[5][10] Baseline and routine monitoring of alanine aminotransferase levels and monitoring for clinical symptoms of liver injury are recommended.[19][20][21]

Diabetic Macular Edema

Combination TZD and insulin therapy have correlated with an increased incidence of diabetic macular edema at 1-year and 10-year follow-up. However, more studies are underway to evaluate confounding factors and define the frequency of this adverse event.[22][23]

Increased Ovulation and Teratogenic Effects

Patients with polycystic ovarian syndrome have shown an increased ovulation rate when using TZD and other insulin sensitizers. This effect may result in ovulation in some premenopausal, anovulatory women, leading to improved rates of spontaneous pregnancy. However, TZDs have also been shown to have some teratogenic potential by decreasing fetal maturation. Premenopausal women should use contraception if they are not trying to conceive and switch to another insulin sensitizer, such as metformin, after conception.[24]

Contraindications

When considering management for T2DM, primary interventions should be lifestyle changes such as diet, exercise, and weight reduction. First-line monotherapy should be metformin or sulfonylureas due to their favorable side effect profiles. However, TZDs may be used as monotherapy or as combination therapy when first-line medications are contraindicated. TZDs may be necessary for high-risk hypoglycemic patients; however, the contraindications require evaluation before starting treatment.

There are several contraindications for using thiazolidinediones, including:

  • Heart failure (New York Heart Association class III, IV): The American Heart Association and the American Diabetes Association has stated that patients with New York Heart Association class III, IV symptomatic heart failure should use TZD at the lowest possible dose or not at all due to risk of fluid retention and diastolic heart dysfunction.[12]
  • Moderate to severe hepatic impairment: Troglitazone was removed from the market due to hepatoxicity. While rosiglitazone or pioglitazone have not shown the same hepatotoxic effects, the recommendation is still that patients undergo baseline and periodic monitoring of liver function. Patients with AST or ALT greater than or equal to 3 times the upper reference limit should discontinue TZD therapy.[25]
  • Bladder cancer: Pioglitazone should not be used in patients with active bladder cancer. In patients with a history of bladder cancer, the risk of recurrence versus the benefits of glycemic control should merit consideration before starting pioglitazone treatment. Rosiglitazone has not shown similar risks of bladder cancer.[18]
  • Pregnancy: The FDA labels TZDs as pregnancy class C with teratogenic potential, as PPAR-gamma is necessary for terminal differentiation of the trophoblast and placental vascularization. Pregnant patients should switch to another insulin sensitizer, such as metformin.[24]
  • High risk of fractures: Due to increased fracture risk, patients who are at a high risk of fractures, such as those with a history of osteoporosis, postmenopausal women, or patients taking other medications that increase fracture risk (such as glucocorticoids and PPIs), should not start on TZD therapy.[1][14][15][16][17]
  • Cytochromes CYP 2C8 and CYP 3A4 are necessary for the metabolism of TZDs; therefore, cytochrome inducers and inhibitors should be used with caution as these medications may affect the drug plasma levels of TZDs.

Monitoring

Before beginning TZD therapy and periodically during treatment, patients should have liver function tests (LFT) evaluated. If LFTs are greater than or equal to 3 times the upper limit, then TZD should not be started or should be discontinued. Additionally, physicians should monitor for clinical symptoms of hepatic injury, such as jaundice or dark urine.[10] Clinicians need to monitor patients’ bodyweight to detect possible fluid overload. Signs and symptoms of fluid overload or heart failure, such as rapid weight gain, peripheral edema, dyspnea, S3 heart sounds, or decreased ejection fraction, require close monitoring. HbA1c should be monitored at least twice a year to assess glycemic control and consider dosage adjustments.[13][26]

Enhancing Healthcare Team Outcomes

The use of thiazolidinediones in the management of T2DM requires an interprofessional healthcare team. These agents can help with glycemic control and insulin resistance in patients with functional pancreatic beta-cells. Though they are not first-line agents, they can act synergistically with other oral agents and insulin. They modify gene transcription to increase adiponectin and insulin sensitivity, lower plasma glucose by increasing glucose utilization, decrease plasma fatty acids by increasing fatty acid oxidation, decrease serum triglycerides, and decrease visceral fat. Early use of TZDs in the course of the disease may benefit the pancreas, but there are many long-term dose and duration dependant adverse effects that limit their use. Such effects may include heart failure,  weight gain, and bone density loss.

When properly prescribed and carefully monitored, they can effectively reduce fasting plasma glucose and HbA1c levels in some patients by increasing insulin sensitivity. These adverse effects are why a pharmacist consult may be necessary to verify the dosing regimen, check for interactions, and perform medication reconciliation. To receive maximum benefit from TZDs, patient body weight, liver function, plasma glucose, and HbA1c levels need monitoring at follow-up visits; these are functions that a diabetes nurse educator can perform and keep the prescriber informed regarding progress. In addition to being used as adjunctive therapy for diabetes, they have a place in patients with steatohepatitis since they reduce liver fat in clinical trials. With an appropriate interprofessional team approach to thiazolidinedione therapy, patient outcomes for type 2 diabetes can improve with minimal adverse events. [Level 5]

Review Questions

References

1.
Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013 Jun;13(3):329-41. [PubMed: 23625197]
2.
Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017 May 01;177(5):633-640. [PMC free article: PMC5470366] [PubMed: 28241279]
3.
He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. Medicine (Baltimore). 2016 Oct;95(42):e4947. [PMC free article: PMC5079311] [PubMed: 27759627]
4.
Yamanouchi T. Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Vasc Health Risk Manag. 2010 Apr 15;6:189-97. [PMC free article: PMC2856574] [PubMed: 20407626]
5.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 6, 2017. Antidiabetic Agents. [PMC free article: PMC547852] [PubMed: 31644090]
6.
Vieira R, Souto SB, Sánchez-López E, Machado AL, Severino P, Jose S, Santini A, Fortuna A, García ML, Silva AM, Souto EB. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I. Pharmaceuticals (Basel). 2019 Oct 10;12(4) [PMC free article: PMC6958392] [PubMed: 31658729]
7.
Gor D, Gerber BS, Walton SM, Lee TA, Nutescu EA, Touchette DR. Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey. J Diabetes. 2020 May;12(5):385-395. [PubMed: 31652390]
8.
Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011 Oct;2(4):236-40. [PMC free article: PMC3255347] [PubMed: 22247890]
9.
Choi SS, Park J, Choi JH. Revisiting PPARγ as a target for the treatment of metabolic disorders. BMB Rep. 2014 Nov;47(11):599-608. [PMC free article: PMC4281338] [PubMed: 25154720]
10.
Floyd JS, Barbehenn E, Lurie P, Wolfe SM. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1238-43. [PubMed: 19623674]
11.
DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia. 1981 Sep;21(3):165-71. [PubMed: 7028550]
12.
Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009 Aug 18;339:b2942. [PMC free article: PMC2728804] [PubMed: 19690342]
13.
Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004 Sep 09;351(11):1106-18. [PubMed: 15356308]
14.
Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005 Mar;146(3):1226-35. [PubMed: 15591153]
15.
Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009 Aug 10;169(15):1395-402. [PubMed: 19667303]
16.
Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, Karter AJ, Lee PG, Marrero DG, Selby JV, Subramanian U, Herman WH. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab. 2010 Oct;95(10):4560-5. [PMC free article: PMC3050101] [PubMed: 20631021]
17.
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008 Apr 28;168(8):820-5. [PubMed: 18443256]
18.
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR., PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32(3):187-202. [PubMed: 19338377]
19.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 6, 2018. Pioglitazone. [PMC free article: PMC547852] [PubMed: 31643649]
20.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 6, 2018. Rosiglitazone. [PMC free article: PMC547852] [PubMed: 31643444]
21.
Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002 May;25(5):815-21. [PubMed: 11978674]
22.
Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012 Jul 09;172(13):1005-11. [PubMed: 22688528]
23.
Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009 Apr;147(4):583-586.e1. [PubMed: 19181303]
24.
Froment P, Touraine P. Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS). PPAR Res. 2006;2006:73986. [PMC free article: PMC1779579] [PubMed: 17347533]
25.
Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 2001;24(12):873-88. [PubMed: 11735645]
26.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 07;355(23):2427-43. [PubMed: 17145742]

Disclosure: Julie Eggleton declares no relevant financial relationships with ineligible companies.

Disclosure: Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK551656PMID: 31869120

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...